Risk of Serious Infection Associated with Agents that Target T-Cell Activation and Interleukin-17 and Interleukin-23 Cytokines
Resource type
Journal Article
Author/contributor
- Shoor, Stanford (Author)
Title
Risk of Serious Infection Associated with Agents that Target T-Cell Activation and Interleukin-17 and Interleukin-23 Cytokines
Abstract
Co-stimulatory T-cell inhibitors are used in the treatment of rheumatoid arthritis
and to prevent rejection of renal transplants. Inhibitors of the intereukin (IL-17)
cytokine are indicated for psoriasis, psoriatic arthritis and ankylosing spondylitis
and anti- IL-23 drugs for psoriasis. Serious infections occur in 4.2% to 25.0% of
co-stimulatory inhibitors and 1.0% to 2.0% with IL-17 or IL-23 inhibitors. Underlying
disease, steroid dose greater than 7.5 to 10.0 mg, and comorbidities influence risk
in individual patients. Opportunistic infections or reactivation of tuberculosis are
rare.
Publication
Infectious Disease Clinics
Date
2020/06/01
Volume
34
Issue
2
Pages
179-189
Journal Abbr
Infectious Disease Clinics
Accessed
9/1/21, 3:43 PM
ISSN
0891-5520, 1557-9824
Language
English
Library Catalog
Extra
Publisher: Elsevier
PMID: 32444009
Citation
Shoor, S. (2020). Risk of Serious Infection Associated with Agents that Target T-Cell Activation and Interleukin-17 and Interleukin-23 Cytokines. Infectious Disease Clinics, 34(2), 179–189. https://doi.org/10.1016/j.idc.2020.02.001
HEME-ONC AND CELLULAR THERAPIES
Link to this record